Incyte (INCY) launched to a nine-month high Tuesday after an analyst suggested its portfolio of cancer treatments could net the biotech stock an acquisition offer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,